

EDUCATIONAL MATERIALS
Dissemination of educational materials for
Apixaban Umedica 2.5 mg and 5 mg film-coated tablets
PL 60528/0036-0037

Distribution Plan for Apixaban Umedica Educational Materials

COMMUNICATION PLAN	
Medicinal product(s)	Apixaban Umedica 2.5 mg film-coated tablets Apixaban Umedica 5 mg film-coated tablets
Active substance(s)	Apixaban
Marketing authorisation holder(s)	Umedica Laboratories UK Ltd Office No. G42, The Panorama Park Street Ashford, England TN24 8DF
Safety concern and purpose of the communication	Important identified risks <ul style="list-style-type: none"> • Bleeding Important potential risks <ul style="list-style-type: none"> • Liver Injury • Potential risk of bleeding or thrombosis due to overdose or under dose Missing information <ul style="list-style-type: none"> • Use in patients with severe renal impairment
Approval date of Educational Materials / RMP version number	<ul style="list-style-type: none"> • Approval date of RMP: November 2025 • RMP Version number: 0.2
Target audience and planned distribution path including recipients of educational materials	Patient Card The MAH shall distribute "Patient Card" to patients or care taker of patients. A copy of the Patient Card shall be provided in the carton for Apixaban Umedica 2.5 mg, and 5 mg film-coated Tablets.
Member States / Country where the Educational Materials will be distributed	UK-wide
Dissemination mode	Digital: placing on web-site https://www.medicines.org.uk/emc Paper copy: on request.
Dissemination of educational materials	MAH shall distribute the above-mentioned educational materials prior to launch of the product as per the regulatory requirement.